Biocept Akcia

Biocept PEG

Delisted

PEG Ratio (Pomer cena/zisk k rastu) spoločnosti Biocept (BIOC) k 22. 8. 2026.

PEG

0,00

Naposledy aktualizované:

PEG Ratio (Pomer cena/zisk k rastu) spoločnosti Biocept je 2026 0,00 . PEG Ratio (Pomer cena/zisk k rastu) spoločnosti Biocept bolo 2025 -0,02 . Klesá teda o % vyššie oproti predchádzajúcemu roku.
Access this data via the Eulerpool API

Biocept Analýza akcií

Čo robí Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept je jednou z najobľúbenejších spoločností na Eulerpool.

Často kladené otázky o akcii Biocept

Na Eulerpool nájdete kompletnú historickú evolúciu Biocept PEG Ratio (Pomer cena/zisk k rastu) od roku 2006 – s ročnými hodnotami, grafmi a detailnou analýzou.

PEG pomer upravuje P/E pomer o očakávanú mieru rastu ziskov. PEG pod 1 môže naznačovať podhodnotenú akciu vo vzťahu k jej potenciálu rastu.

PEG = P/E pomer / Očakávaná ročná miera rastu EPS

Aby ste vyhodnotili PEG Ratio (Pomer cena/zisk k rastu)s, je nevyhnutné to porovnať so spoločnosťami v rovnakom odvetví a sektore. Na Eulopoole nájdete priame porovnania medzi spoločnosťami v odvetví pre PEG Ratio (Pomer cena/zisk k rastu).

Dobrá hodnota sa líši v závislosti od odvetvia a fázy vývoja spoločnosti. Na Eulopoole môžete porovnať PEG Ratio (Pomer cena/zisk k rastu)s Biocept s konkurentmi v sektore a priemerom odvetvia, aby ste posúdili, či je atraktívna.

Access this data via the Eulerpool API

Oceňovanie — Biocept

Všetky kľúčové ukazovatele — Biocept